Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda to Shore Up Lifestyle Diseases Area in Japan with New Products
March 8, 2010
- Astellas Licenses Isavuconazole from Basilea
March 8, 2010
- Biogen Idec Aims to Become Leading Company for MS: President Ozaki
March 8, 2010
- “Open Innovation”Essential for Drug Discovery: Dr Sakata of Shionogi
March 8, 2010
- Astellas Begins Tender Offer to Acquire OSI Pharmaceuticals
March 8, 2010
- South Korea Has Advanced Clinical Trial Infrastructures: JPMA Press Tour
March 8, 2010
- Nippon Shinyaku Props Up Marketing Structure for PAH Products
March 8, 2010
- Gov't Should Invest More in R&D: Prof. Taniguchi
March 8, 2010
- Shionogi Licenses Ospemifene from QuatRx
March 8, 2010
- Clexane Prevents Postoperative VTE in Japanese: sanofi-aventis
March 8, 2010
- Makers Should Change Their Marketing Method: Prof. Koyama
March 8, 2010
- 16th Edition of JP to See Sweeping Revisions of “General Rules for Preparations”
March 8, 2010
- Recommendation of Switching PPIs to OTC Status Withheld Again
March 8, 2010
- New NHI Pricing System to Provide Big Opportunity for CROs: Mr Nakamura
March 8, 2010
- Korosho to Call on Public Hospitals for Earlier Price Settlement
March 8, 2010
- Oxiconazole Recommended for Approval as OTC Drugs for Vaginal Candidiasis
March 8, 2010
- 2-Week Restriction on Prescription Impedes Use of New Drugs: Mr Umeda of PhRMA
March 8, 2010
- Dr Hotta Calls For Flexible Approach to Applications Based on Data from Public Domain
March 8, 2010
- Legislation of “Specific Nurses”Proposed by Korosho
March 8, 2010
- Daiichi Sankyo to Set Up Japan Company
March 8, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…